Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab versus investigator's choice for advanced gastric cancer with peritoneal metastasis
ChiCTR1900028626Phase 3Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of catumaxomab in gastric adenocarcinoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall survival. Started Jan 2020; status: recruiting.
02
Drugs
catumaxomab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900028626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028626.